MIRA Reports SKNY-1 Preclinical Study Showing 30% Weight Loss, Lipid Normalization
MIRA Pharmaceuticals achieved peer-reviewed publication for SKNY-1 preclinical data demonstrating dose-dependent 30% weight reduction and improved lipid profiles in an MC4R-deficient zebrafish model. The study also showed attenuated compulsive feeding and nicotine-seeking behaviors, highlighting SKNY-1’s CB1/CB2 modulation and selective MAO-B inhibition profile.
1. Manuscript Acceptance
MIRA Pharmaceuticals announced acceptance of a peer-reviewed manuscript in the International Journal of Molecular Sciences detailing the preclinical pharmacology of SKNY-1, its oral investigational candidate for obesity and nicotine addiction.
2. Key Preclinical Findings
In an MC4R-deficient zebrafish model, oral SKNY-1 produced a dose-dependent body weight reduction of approximately 30%, normalized total cholesterol and LDL levels, and reduced hepatic triglyceride accumulation without affecting lean mass.
3. Behavioral Outcomes
SKNY-1 administration attenuated high-calorie feeding and nicotine-seeking behaviors in multiple paradigms, and modulated leptin and ghrelin gene expression toward wild-type levels, indicating dual metabolic and reward-pathway engagement.
4. Mechanism and Next Steps
SKNY-1 exhibited partial CB1 agonism, CB2 activation and selective MAO-B inhibition; MIRA plans additional mammalian studies, pharmacokinetics, toxicology assessments and regulatory review before clinical trials.